PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

Brain Communications

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Brain Communications has 1 tracked paper indexed in Blossom (2024) from 9 authors, most often covering Psilocybin, across Depressive Disorders and Treatment-Resistant Depression (TRD).

Published Papers

Open Accessindividual

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Using large-scale brain modelling and dynamic sensitivity analysis of resting-state data in responders versus non-responders, the study identified specific brain regions whose perturbation predicts a transition from depressive to healthy brain dynamics following psilocybin therapy. These regions co-localise with in vivo 5-HT2A and 5-HT1A receptor density maps, providing causal mechanistic evidence that serotonergic targets mediate psilocybin's therapeutic effect in treatment-resistant depression.

Published
February 15, 2024
Journal
Brain Communications
Authors
Vohryzek, J., Cabral, J., Lord, L. D., Fernandes, H. M., Roseman, L., Nutt, D. J., Carhart-Harris, R. L., Deco, G., Kringelbach, M. L.

Quick Facts

Papers Indexed
1
h-Index
42
Open Access
Yes
Publisher
Oxford University Press
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.